Respiratory inflammation is the lung’s immune response to harmful triggers, and it sits at the center of nearly every common lung disease, from a bout of pneumonia to decades of asthma or chronic obstructive pulmonary disease (COPD). In its acute form, inflammation helps clear infections and repair tissue; in its chronic form, it damages the very airways it is meant to protect. Understanding the causes, how symptoms differ between types, and what treatments are available can help you make sense of a diagnosis and the options that follow.
What Happens Inside Inflamed Airways
When the lungs encounter something harmful, the immune system launches a cascade of cellular activity. Inflammatory cells, including neutrophils, eosinophils, and macrophages, rush to the site and release signaling molecules called cytokines. Those cytokines recruit still more immune cells and amplify the response. In a well-functioning system, this resolves quickly once the threat is gone. In lung diseases, the process either spirals out of control (as in acute respiratory distress syndrome) or never fully shuts off (as in asthma and COPD).1Europe PMC. Inflammatory mechanisms in the lung
The airway lining itself plays a surprisingly active role. Epithelial cells lining the airways are the first thing inhaled particles, allergens, and pathogens touch. When those cells detect a threat through pattern-recognition receptors, they release alarm signals, specifically a group of cytokines known as TSLP, IL-33, and IL-25. These alarmins act as upstream switches that activate both the innate immune system (your rapid first-response defenses) and the adaptive immune system (the slower but more targeted response), setting the tone for the entire inflammatory reaction.2PubMed Central. The Role of Airway Epithelial Cell Alarmins in Asthma3PubMed. Epithelial alarmins TSLP, IL-33, and IL-25 in asthma pathogenesis: mechanistic roles and therapeutic implications
Infectious Causes
Bacteria, viruses, and fungi are the most straightforward triggers of lung inflammation. A viral respiratory infection like influenza or COVID-19 prompts the immune system to flood the airways with neutrophils and other inflammatory cells. When this response is proportional, it clears the pathogen and inflammation settles. When it is not, the virus replicates unchecked and the immune reaction itself causes collateral damage. Animal research illustrates the stakes: mice whose neutrophils responded quickly and vigorously to influenza cleared the virus, while mice with a sluggish early neutrophil response developed uncontrolled viral growth, severe airway inflammation, and vascular leakage in the lungs.4PLOS Pathogens. Deficient neutrophil responses early in influenza infection promote viral replication and pulmonary inflammation
Bacterial pneumonia follows a broadly similar pattern: pathogens invade, immune cells mobilize, and the alveoli (the tiny air sacs where oxygen enters the blood) fill with fluid and inflammatory debris. That fluid is what shows up as a white patch on a chest X-ray and what makes it hard to breathe. In most healthy adults, antibiotics or the immune system itself resolve the infection within days to weeks. But in people with weakened immunity or in elderly populations, the inflammatory process can progress to acute respiratory distress syndrome, a life-threatening condition.
Environmental and Occupational Triggers
You do not need a pathogen to inflame your lungs. Inhaled irritants, especially fine particulate matter from air pollution, cigarette smoke, workplace dust, and chemical fumes, trigger similar inflammatory pathways. Fine particles smaller than 2.5 micrometers (PM2.5) are particularly damaging because they penetrate deep into the lungs and generate reactive oxygen species, molecules that damage cells at the molecular level. Research in mice has shown that PM2.5 exposure activates the NF-κB inflammatory pathway, triggers cytokine release, and recruits inflammatory cells into the lung tissue. Critically, this oxidative stress and inflammation persisted even after exposure stopped, suggesting the damage can outlast the pollution itself.5PubMed. Oxidative stress and inflammation induced by air pollution-derived PM(2.5) persist in the lungs of mice after cessation of their sub-chronic exposure
This lingering effect matters for anyone living in areas with seasonal poor air quality, or for workers regularly exposed to dust and fumes. The fact that lung inflammation does not always resolve once you step into clean air helps explain why chronic exposure can lead to permanent changes in the airways and raise the risk of chronic inflammatory lung diseases and even cancer.
Allergens and the Type 2 Immune Response
Allergic inflammation in the lungs follows a somewhat different script. When you inhale an allergen like house dust mites, pet dander, or mold spores, the immune system can mount what is called a type 2 response, driven largely by a specific set of immune cells and cytokines (IL-4, IL-5, and IL-13). This type of response characteristically recruits eosinophils, a type of white blood cell, into the airway tissue and promotes the production of IgE antibodies.
A common misconception is that IgE antibodies are the sole driver of allergic airway inflammation. While IgE plays an important amplifying role, research in mice lacking the ability to produce IgE found that allergen exposure still caused substantial eosinophil infiltration into the lungs and airways.6PubMed. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma This means IgE is part of the allergic story, but not the whole thing. It also helps explain why some people with asthma have low IgE levels yet still have eosinophilic airway inflammation.
On a more hopeful note, mucosal vaccines are being investigated that could prevent allergic airway inflammation before it starts. One experimental approach using a bacterial preparation called MV130 has been shown in mice to prevent house-dust-mite-induced eosinophilic airway inflammation and restore normal airway function, partly by steering the immune system away from a type 2 response and toward a type 1 and anti-inflammatory profile.7PubMed Central. A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
How Chronic Inflammation Reshapes the Airways
When inflammation sticks around, it does more than cause symptoms. It physically remodels the airways. In asthma, airway smooth muscle plays a central role. Chronic inflammation causes the smooth muscle layer to thicken and become hyperresponsive, meaning it contracts too easily and too forcefully in response to triggers. This muscle thickening also impairs the ability of the airways to relax fully, which is why people with long-standing asthma often have some degree of airflow limitation even between attacks.8Europe PMC / Journal of Applied Physiology. Airway smooth muscle in the pathophysiology and treatment of asthma
In COPD, the remodeling story is different. Chronic inflammation driven largely by neutrophils damages the walls of the alveoli (leading to emphysema) and the lining of the airways (leading to chronic bronchitis). Neutrophil overactivity is a hallmark of COPD, and the resulting tissue destruction is essentially irreversible. Microbial imbalance in the airways, sometimes called dysbiosis, further feeds this cycle by keeping the immune system in a state of low-grade activation even between flare-ups.9Europe PMC. COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets
When Inflammation Becomes Life-Threatening
Acute respiratory distress syndrome, or ARDS, represents the extreme end of lung inflammation. It can develop from severe pneumonia, sepsis, inhalation injuries, or other major insults. What happens, in brief, is that uncontrolled inflammatory pathways break down the barrier between the alveoli and the tiny blood vessels surrounding them. Fluid leaks into the air sacs, and the lungs can no longer exchange oxygen effectively.10PubMed Central. Cytokine storm in acute respiratory distress syndrome
In the worst cases, this process triggers a cytokine storm, a dangerous feedback loop where the release of inflammatory mediators like IL-6, IL-8, and TNF spirals beyond control. These cytokines recruit more immune cells, which release damaging molecules including reactive oxygen species and tissue-destroying enzymes, which further injure the alveolar walls, which triggers more cytokine release. The result is respiratory failure and, if untreated, multi-organ damage.11PubMed Central. Progress in cytokine research for ARDS: A comprehensive review – Section: Immune imbalance This is the process that made COVID-19 so deadly in a subset of patients and the reason intensive-care treatment for ARDS focuses heavily on dampening the immune response alongside supporting breathing.
Recognizing the Type of Inflammation
Respiratory inflammation does not look the same in every patient, and knowing the type matters because it changes treatment decisions. One of the most useful and accessible tools is fractional exhaled nitric oxide, or FeNO. This is a simple breath test that measures the level of nitric oxide gas in your exhaled air, which rises when type 2 (eosinophilic) airway inflammation is present. It is quick, noninvasive, and can be done in a doctor’s office.12PubMed Central. Update on the Role of FeNO in Asthma Management FeNO has become well established in asthma management and is increasingly used in COPD and bronchiectasis as well.13PubMed Central. Fractional Exhaled Nitric Oxide (FeNO) as a Biomarker of Lower Airway Eosinophilic Inflammation: Benefits and Limitations
For a more detailed picture, doctors sometimes use induced sputum analysis, where you inhale a saline mist that helps you cough up mucus from the lower airways, and the sample is examined under a microscope. This allows clinicians to see exactly which inflammatory cells dominate. In asthma, one study found that roughly 47% of patients had an eosinophilic pattern, about 16% had a neutrophilic pattern, and the rest were mixed or had relatively low cell counts.14PubMed Central. Characteristics of Induced-Sputum Inflammatory Phenotypes in Adults with Asthma: Predictors of Bronchial Eosinophilia In COPD, the picture flips: neutrophils tend to dominate while eosinophil counts are lower compared to asthma.15PubMed Central. Sputum cell count: biomarkers in the differentiation of asthma, COPD and asthma-COPD overlap This distinction is more than academic; it determines which medications are likely to work.
Treatment With Inhaled Corticosteroids
Inhaled corticosteroids remain the backbone of treatment for chronic airway inflammation, especially in asthma. They work by switching off the genes responsible for producing inflammatory proteins, effectively dialing down the immune overreaction in the airways.16PubMed Central. Inhaled Corticosteroids For most people with mild to moderate asthma, a daily inhaled steroid is enough to keep inflammation in check and prevent attacks.
However, inhaled corticosteroids are less effective in neutrophil-driven inflammation, which is why they help most asthma patients but have a more complicated track record in COPD. The mechanism behind this resistance involves reduced levels of a specific enzyme (HDAC2) in the cells of people with COPD and severe asthma, which blunts the steroid’s ability to shut down inflammatory genes. This is one of the reasons COPD management relies more heavily on bronchodilators and why severe asthma often requires additional therapies.
Biologic Therapies for Severe Cases
When standard treatments fall short, biologic therapies have transformed the outlook for people with severe asthma. Seven monoclonal antibody drugs are currently approved, each targeting a specific molecule in the inflammatory chain. Some target IgE (omalizumab), others target IL-5 or its receptor (mepolizumab, reslizumab, benralizumab, depemokimab), one targets the IL-4 receptor (dupilumab), and one targets the alarmin TSLP (tezepelumab). All have been shown to cut exacerbation rates, reduce the need for oral steroids, and improve lung function.17PubMed Central. Current and Emerging Biologic Therapies for Severe Asthma
A meta-analysis of trials for these drugs found that IL-5 inhibitors and IL-4/IL-13-blocking biologics both improved lung function and cut annual exacerbation rates, with IL-5 inhibitors also substantially reducing oral corticosteroid use.18Journal of Allergy and Clinical Immunology: Global. Biologic therapies targeting type 2 cytokines are effective at improving asthma symptoms and control—a systematic review and meta-analysis Drugs that block the IL-4/IL-13 pathway may disrupt a broader range of the type 2 inflammatory response compared to those that only target IL-5, which mainly reduces eosinophil numbers.19Current opinion in allergy and clinical immunology. Interleukin-4/interleukin-13 versus interleukin-5: A comparison of molecular targets in biologic therapy for the treatment of severe asthma This is why the choice of biologic depends on the specific pattern of inflammation each patient has, which brings the diagnostic tools discussed earlier back into practical relevance.
Inflammation Beyond the Lungs
Chronic respiratory inflammation does not always stay confined to the chest. COPD, in particular, is associated with systemic inflammation that raises the risk of cardiovascular disease and lung cancer. The inflammatory cells and signaling molecules active in the lungs spill into the general circulation and appear to promote disease processes elsewhere in the body.20PubMed Central. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer This is why people with moderate to severe COPD are monitored not just for breathing problems but for heart disease as well. It also underscores that treating lung inflammation is not purely about lung function; it may have protective effects on the rest of the body.
The Gut-Lung Connection
One of the more surprising areas of research in recent years is the discovery that the bacteria in your gut influence inflammation in your lungs. This bidirectional communication pathway, called the gut-lung axis, works through microbial metabolites, immune-cell programming, and barrier integrity in both the gut lining and the airway lining.21PubMed Central. Gut Microbiota-Immune Interactions in Chronic Lung Diseases: An Emerging Cross-Disease Perspective Gut-Lung Axis in Chronic Lung Disease
Certain metabolites produced by gut bacteria, including short-chain fatty acids like butyrate and propionate, travel through the bloodstream and appear to suppress lung inflammation and support immune balance. Tryptophan metabolites, secondary bile acids, and polyamines produced by colonic bacteria have also been linked to reduced severity of respiratory diseases. This line of research is still young, but it raises the possibility that diet, probiotics, or other gut-focused interventions could become part of managing chronic lung inflammation in the future.
How Age Shapes Lung Inflammation
The way your immune system handles lung inflammation changes at both ends of life. In older adults, the immune system undergoes a gradual decline known as immunosenescence, accompanied by a baseline state of low-grade chronic inflammation sometimes called “inflamm-aging.” This combination predisposes older people to lung infections, makes them more vulnerable to ARDS, and shapes specific disease patterns including late-onset asthma, COPD, and pulmonary fibrosis.22Europe PMC / Hindawi. The Impact of Immunosenescence on Pulmonary Disease Late-onset asthma in particular tends to differ from childhood asthma. It is often less allergic, more neutrophilic, and less responsive to standard inhaled steroids, which frustrates both patients and clinicians who expect the same treatments to work.
Children, on the other hand, have immature immune systems that can overreact in some ways (frequent viral wheezing episodes) while underreacting in others (difficulty mounting a robust early antiviral defense). The developing airway in childhood is also more susceptible to lasting remodeling from early inflammatory insults, which is one reason repeated respiratory infections or uncontrolled childhood asthma can affect lung function into adulthood.
Reducing Exposure and Indoor Air Quality
Because environmental triggers are a major driver of respiratory inflammation, reducing exposure can have a measurable effect. A randomized trial found that indoor air purification significantly reduced FeNO levels, the marker of type 2 airway inflammation, by about 17% in the treatment group compared to controls.23PubMed Central. Cardiopulmonary Benefits of Reducing Indoor Particles of Outdoor Origin: a Randomized Double-Blind Crossover Trial of Air Purifiers While 17% may not sound dramatic, for someone with persistent airway inflammation from outdoor pollution, that reduction represents a meaningful shift toward healthier airways without adding a single medication.
Beyond air purifiers, practical steps include keeping windows closed during high-pollution days, using exhaust fans while cooking with gas stoves, removing carpeting in bedrooms if dust mites are a known trigger, and avoiding indoor smoking. For occupational exposures, proper respiratory protection and ventilation are the most effective interventions. None of these replace medical treatment when disease is established, but they address the root trigger rather than just the downstream inflammation.
Circadian Rhythms and Airway Inflammation
If you have noticed that asthma symptoms tend to worsen at night or in the early morning, your body clock is part of the reason. Lung immune function follows circadian rhythms, and research has shown that airway hyperresponsiveness in mice peaks at the transition from rest to activity. Mice lacking a key clock gene called Rev-erbα lost this time-of-day variation entirely, confirming that the circadian clock directly gates the inflammatory response in the airways.24PubMed Central. Circadian asthma airway responses are gated by REV-ERBα
Disrupted circadian rhythms from shift work, jet lag, or poor sleep patterns can worsen immune regulation and amplify asthma symptoms.25PubMed Central. The Circadian Rhythm of Asthma Immune Metabolism This has practical implications: timing medication to match the body’s inflammatory peaks, a concept called chronotherapy, could make existing drugs work better. Some clinicians already advise patients with nocturnal asthma to take their controller medications in the evening rather than the morning, though the formal evidence base for optimized dosing schedules is still being built.
Post-Viral Airway Sensitivity
A respiratory infection that seemed to resolve can leave behind persistent airway inflammation and sensitivity. This was widely recognized during the COVID-19 pandemic, when large numbers of people developed lingering respiratory symptoms after their initial infection cleared. A study of over 4,200 patients with long COVID found that about 80% tested positive on bronchial provocation testing, meaning their airways reacted excessively to mild stimuli well after the virus was gone.26Frontiers in Medicine. Diagnostic value of lung function tests in long COVID: analysis of positive bronchial provocation test outcomes The study also found measurable differences in lung function parameters between those who tested positive and those who did not, though the individual tests had limited ability to predict which patients would test positive.
Post-viral airway hyperreactivity is not unique to COVID-19. It has been described after influenza, respiratory syncytial virus, and other common respiratory infections for decades. The mechanism likely involves residual inflammation and epithelial damage that leaves the airway lining in a sensitized state. For most people, this resolves over weeks to months. For some, it becomes a gateway to longer-term conditions, particularly if they had underlying risk factors like allergic sensitization or pre-existing mild asthma that had not yet been diagnosed.